98 related articles for article (PubMed ID: 1560443)
1. Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides.
Tam TF; Carrière J; MacDonald D; Castelhano AL; Pliura DH; Dewdney NJ; Thomas EM; Bach C; Barnett J; Chan H
J Med Chem; 1992 Apr; 35(7):1318-20. PubMed ID: 1560443
[No Abstract] [Full Text] [Related]
2. Peptide aldehydes as inhibitors of HIV protease.
Sarubbi E; Seneci PF; Angelastro MR; Peet NP; Denaro M; Islam K
FEBS Lett; 1993 Mar; 319(3):253-6. PubMed ID: 8458418
[TBL] [Abstract][Full Text] [Related]
3. Pentacycloundecane lactam vs lactone norstatine type protease HIV inhibitors: binding energy calculations and DFT study.
Honarparvar B; Pawar SA; Alves CN; Lameira J; Maguire GE; Silva JR; Govender T; Kruger HG
J Biomed Sci; 2015 Feb; 22(1):15. PubMed ID: 25889635
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules.
Waller CL; Oprea TI; Giolitti A; Marshall GR
J Med Chem; 1993 Dec; 36(26):4152-60. PubMed ID: 8277496
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502.
Lingham RB; Arison BH; Colwell LF; Hsu A; Dezeny G; Thompson WJ; Garrity GM; Gagliardi MM; Hartner FW; Darke PL
Biochem Biophys Res Commun; 1991 Dec; 181(3):1456-61. PubMed ID: 1764098
[TBL] [Abstract][Full Text] [Related]
6. Potent HIV-1 protease inhibitors with antiviral activities in vitro.
Sham HL; Betebenner DA; Wideburg NE; Saldivar AC; Kohlbrenner WE; Vasavanonda S; Kempf DJ; Norbeck DW; Zhao C; Clement JJ
Biochem Biophys Res Commun; 1991 Mar; 175(3):914-9. PubMed ID: 2025263
[TBL] [Abstract][Full Text] [Related]
7. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
Quéré L; Wenger T; Schramm HJ
Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
Marastoni M; Baldisserotto A; Trapella C; McDonald J; Bortolotti F; Tomatis R
Eur J Med Chem; 2005 May; 40(5):445-51. PubMed ID: 15893018
[TBL] [Abstract][Full Text] [Related]
9. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 protease by short peptides derived from the terminal segments of the protease.
Schramm HJ; Breipohl G; Hansen J; Henke S; Jaeger E; Meichsner C; Riess G; Ruppert D; Rücknagel KP; Schäfer W
Biochem Biophys Res Commun; 1992 Apr; 184(2):980-5. PubMed ID: 1575762
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
[TBL] [Abstract][Full Text] [Related]
12. Competitive inhibition of HIV-1 protease by 4-hydroxy-benzopyran-2-ones and by 4-hydroxy-6-phenylpyran-2-ones.
Tummino PJ; Ferguson D; Hupe L; Hupe D
Biochem Biophys Res Commun; 1994 May; 200(3):1658-64. PubMed ID: 8185622
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
Thompson WJ; Fitzgerald PM; Holloway MK; Emini EA; Darke PL; McKeever BM; Schleif WA; Quintero JC; Zugay JA; Tucker TJ
J Med Chem; 1992 May; 35(10):1685-701. PubMed ID: 1588551
[TBL] [Abstract][Full Text] [Related]
14. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
[TBL] [Abstract][Full Text] [Related]
16. Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.
Righi G; Ciambrone S; Bonini C; Campaner P
Bioorg Med Chem; 2008 Jan; 16(2):902-8. PubMed ID: 17964171
[TBL] [Abstract][Full Text] [Related]
17. A symmetric inhibitor binds HIV-1 protease asymmetrically.
Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
[TBL] [Abstract][Full Text] [Related]
18. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Qiu X; Zhao GD; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
[TBL] [Abstract][Full Text] [Related]
20. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors.
Brik A; Muldoon J; Lin YC; Elder JH; Goodsell DS; Olson AJ; Fokin VV; Sharpless KB; Wong CH
Chembiochem; 2003 Nov; 4(11):1246-8. PubMed ID: 14613121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
